Epidemiological Study for Urologic Cancer in Korea (1998-2002) / 대한비뇨기과학회지

PURPOSE: To evaluate the incidence of urologic cancer in Korea. MATERIALS AND METHODS: Between January 1998 and December 2002 the Korean Urologic Oncology Society (KUOS) decided to evaluate the incidence of Korean urologic cancer. The URO-DMS data obtained by 86 training hospital was analyzed. First, the disease code was simplified; for example, renal cell carcinoma (C64), and thereafter, evaluated for incidence and prevalence, etc. RESULTS: A total of 35,480 patients were newly diagnosed over this period. Bladder cancer was the most common (42.9%) urologic cancer, followed by prostate (26.4%), kidney (22.4%), ureter (3.7%), renal pelvis (3.0%), testis (2.8%), penile (0.2%), urethral (0.1%) and scrotal cancers (0.1%). Male patients outnumbered the females by a ratio of 4.4:1. The incidence rates per 100,000 males for prostate and testicular cancers were 7.73 and 0.81, respectively. The incidence rates per 100,000 persons for bladder, renal, ureter and renal pelvis cancers were 6.36, 3.30, 0.55 and 0.44, respectively. Cancers of the prostate and kidney increased rapidly, but the others increased steadily. CONCLUSIONS: It is hoped that these results would contribute to cancer research and control of cancers in Korea.

Metastatic renal cell carcinoma in the contralateral adrenal gland of a 65 year old male 10 years after radical nephrectomy

A case of a 65 year old male from Tondo, Manila with metastatic Renal Cell Carcinoma (RCC) in the contralateral adrenal gland is presented. He underwent a left radical nephrectomy back in May 1992 after which he remained asymptomatic. Only the finding of a right adrenal mass 10 years later would stand to challenge his "cured" state. The steps that lead to the diagnosis and the subsequent management of his case are discussed here. (Author)

Study on the Histopathological Changes of the Subrenal Capsular Implantation of the Human Urologic Cancers / 대한비뇨기과학회지

The selection of the chemotherapeutic agents for the treatment of the urologic malignancy was one of the difficult problem in urologic practice. After the development of the in vivo sensitivity test using subrenal capsular implantation of the cancer tissue, a lot of the application of this assay were performed in various field of the advanced malignancies. We examined the histopathological changes of the implanted urologic cancer tissues under the renal capsule of the mice. The specimens, implanted under the renal capsule, were 14 cases of the bladder cancer, 2 cases of the renal cell carcinoma and one case of the prostatic carcinoma. In experiment, we used 472 immunocompetent normal mice and divide them into two groups, non-immunosuppressed normal mice and immunosuppressed group with intravenous infusion of the cyclophosphamide 200mg/kg 24 hours prior to assay. As the control group, we used athymic nude mice for human urologic cancer and C3H/He strain for MBT-2 bladder cancer. The results we found were as follow ; 1. The growth of the implanted cancer tissues was noticed in 270 mice among 291 which were sacrificed until the 6th postoperative day and the take rate was 92.8%. 2. The growth of the implanted cancer tissues was continuous until the 6th postoperative day progressively but reduced thereafter in immunocompetent group. But in immunosuppressed group, it showed progressive growth of the implanted tissue until the 8th postoperative day. The growth of the control group was similar to the immunosuppressed group, until the 6th postoperative day. 3. Calculation of the proportion of the host cellular infiltration in total dimension of the grafted tissue was done and in immunocompetent group, the 4th postoperative day group was 27.3%, the 6th postoperative group was 89.4% and the 8th postoperative group was 100%. But in contrast in immunosuppressed group, at the 4th postoperative day group was less than 10%, the 6th postoperative day was 29.4% and at the 8th postoperative day group was 91.7%. With above histopathological study, we conclude that the most easy and reasonable subrenal capsular assay(SRCA) in the in vivo chemosensitivity test for the selection of the anticancer chemotherapeutic agent for the treatment of the malignancy is the test performed under the immunosuppressed state with cyclophosphamide, 24 hours prior to SRCA, and the results is the most proper at the examination at postoperative 6th day after implantation.

Antibody Dependent Cell-Mediated Cytotoxicity in Patients with Urologic Cancers: A Change by Surgical Operation, Histologic Grades and Clinical Stages / 대한비뇨기과학회지

In an attempt to evaluate the immune competence of urologic cancer patients, antibody-dependent cell-mediated cytotoxicity (ADCC) were performed in thirty-four patients and same numbers of age and sex matched normal controls. Also we compared of the level of ADCC before and after the operation. Concomittantly the values of ADCC were examined by histological grading and clinical staging. We used 51Cr-labelled chicken erythrocytes sensitized with 7s rabbit anti-chicken erythrocytes antibody as target cells and patient peripheral mononuclear cells as effector cells. 1. Effector cells of the patients with the urologic cancer showed significantly lower ADCC than those of normal controls. 1) All urologic cancer. Controls 41.4+/-6.0% (n=34) Preoperation 22.1+/-6.8% (n=34) 2) Transitional cell carcinoma of the renal pelvis and the bladder. Controls 41.7+/-6.1% (n=28) Preoperation 22.5+/-6.3% (n=28) 3)Non-transitional cell carcinoma(renal cell Ca. prostate ca. penis ca. seminoma). Controls 40.2+/-5.9% (n=6) Preoperation 20.6+/-4.6% (n=6) 2. In the patients with the transitional cell carcinoma of the bladder and the renal pelvis, highly graded patients had tendency to have lower response of ADCC. Grade I 27.3+/-4.0% (n=14) Grade II 19.9+/-4.l% (n=7) Grade III 15.5+/-3.2% (n=7) 3. In the patients with bladder carcinoma highly staged patients had tendency have lower response of ADDC. Stage T